Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADD UP trial of albendazole added to anti-TNF monotherapy in Crohn's disease
NL-OMON48703Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in Crohn's disease and inflammatory bowel disease (IBD) comparing Albendazole + continued anti-TNF with Placebo + continued anti-TNF (2 arms). Primary endpoint: Absence of ulcers after 12 weeks. Started Oct 2018; status: active, not recruiting.
02
Drugs
albendazole
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON48703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48703.